Peritoneovenous shunt for palliation of malignant ascites
- PMID: 6174196
- DOI: 10.1002/1097-0142(19820201)49:3<600::aid-cncr2820490333>3.0.co;2-t
Peritoneovenous shunt for palliation of malignant ascites
Abstract
Forty patients with malignant ascites refractory to conventional medical management had peritoneovenous shunt for palliation. The shunt provided effective palliation in 28 with decrease in weight, abdominal girth, number of paracenteses required and increase in urine output. These patients also had improvement in strength, appetite and ambulation. Complications such as hemodilution, volume overload, and sepsis do not contraindicate surgery. In 12 patients with high ascitic fluid protein content (4.5 g/liter) and a large number of malignant cells, loculated ascites and prior severe renal and cardiac disease, the shunt did not provide palliation. Peritoneovenous shunt appears to provide effective palliation in carefully selected patients with refractory malignant ascites.
Similar articles
-
Peritoneovenous shunt for intractable malignant ascites. A single case report of metastatic peritoneal mesothelioma implanted via LeVeen shunt.Cancer. 1984 Nov 15;54(10):2231-3. doi: 10.1002/1097-0142(19841115)54:10<2231::aid-cncr2820541027>3.0.co;2-i. Cancer. 1984. PMID: 6207908
-
Control of malignant ascites by peritoneovenous shunting.Cancer. 1984 Nov 15;54(10):2226-30. doi: 10.1002/1097-0142(19841115)54:10<2226::aid-cncr2820541026>3.0.co;2-7. Cancer. 1984. PMID: 6207907
-
Palliation of malignant ascites by the Denver peritoneovenous shunt.Ann R Coll Surg Engl. 1984 Sep;66(5):340-3. Ann R Coll Surg Engl. 1984. PMID: 6207757 Free PMC article.
-
Denver peritoneovenous shunts for the management of malignant ascites: a review of the literature in the post LeVeen Era.Am Surg. 2011 Aug;77(8):1070-5. doi: 10.1177/000313481107700830. Am Surg. 2011. PMID: 21944526 Review.
-
The LeVeen shunt.Annu Rev Med. 1985;36:453-69. doi: 10.1146/annurev.me.36.020185.002321. Annu Rev Med. 1985. PMID: 3888061 Review.
Cited by
-
Peritoneovenous shunt for pancreatic ascites.Dig Dis Sci. 1987 May;32(5):550-3. doi: 10.1007/BF01296040. Dig Dis Sci. 1987. PMID: 3568942
-
Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer.Clin Pharmacol. 2013 Oct 3;5(Suppl 1):55-61. doi: 10.2147/CPAA.S45885. Clin Pharmacol. 2013. PMID: 24124397 Free PMC article. Review.
-
Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts.Br Med J (Clin Res Ed). 1984 Mar 10;288(6419):749-51. doi: 10.1136/bmj.288.6419.749. Br Med J (Clin Res Ed). 1984. PMID: 6423061 Free PMC article.
-
Feasibility of externalized peritoneovenous shunt (EPVS) for malignant ascites.World J Surg Oncol. 2011 Jul 21;9:82. doi: 10.1186/1477-7819-9-82. World J Surg Oncol. 2011. PMID: 21777451 Free PMC article.
-
Peritoneovenous shunts in malignant ascites.Dig Dis Sci. 1985 Nov;30(11):1104-7. doi: 10.1007/BF01315609. Dig Dis Sci. 1985. PMID: 2996864